Showing results (261-270 of 423) with videos related to

Sort By:
Pageof 43
Circulation|June 27, 2018
Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney FunctionBrendon L Neuen, Toshiaki Ohkuma, Bruce Neal, et al.
International Journal of Cardiology|June 23, 2020
The effects of combination canagliflozin and glucagon-like peptide-1 receptor agonist therapy on intermediate markers of cardiovascular risk in the CANVAS programClare Arnott, Brendon L Neuen, Hiddo J L Heerspink, et al.
BMJ Open|August 22, 2020
SAFety, Effectiveness of care and Resource use among Australian Hospitals (SAFER Hospitals): a protocol for a population-wide cohort study of outcomes of hospital careIsuru Ranasinghe, Sadia Hossain, Anna Ali, et al.
Clinical Journal of the American Society of Nephrology : CJASN|March 31, 2023
Glycemic Control and Effects of Canagliflozin in Reducing Albuminuria and eGFR: A Post Hoc Analysis of the CREDENCE TrialSjoukje van der Hoek, Niels Jongs, Megumi Oshima, et al.
Kidney International|December 14, 2012
Circulating bone morphogenetic protein-7 and transforming growth factor-β1 are better predictors of renal end points in patients with type 2 diabetes mellitusMuh Geot Wong, Vlado Perkovic, Mark Woodward, et al.
BMJ Global Health|January 26, 2022
Prevalence of chronic kidney disease in Asia: a systematic review and analysisThaminda Liyanage, Tadashi Toyama, Carinna Hockham, et al.
Kidney International|January 22, 2026
A secondary analysis of the TESTING trial predicted individual patient response to corticosteroid treatment in IgA nephropathyMark Canney, Sana Shan, Lee Er, et al.
Diabetes, Obesity & Metabolism|August 14, 2023
Estimated lifetime benefit of novel pharmacological therapies in patients with type 2 diabetes and chronic kidney disease: A joint analysis of randomized controlled clinical trialsHiddo J L Heerspink, Priya Vart, Niels Jongs, et al.
Kidney International Reports|December 22, 2025
Evaluating Sibeprenlimab in IgA Nephropathy - Rationale and Baseline Data from the VISIONARY TrialVlado Perkovic, Jonathan Barratt, Richard Lafayette, et al.
Diabetes Care|July 29, 2025
Effects of Semaglutide With or Without Concomitant Mineralocorticoid Receptor Antagonist Use in Participants With Type 2 Diabetes and Chronic Kidney Disease: A FLOW Trial Prespecified Secondary AnalysisPeter Rossing, George Bakris, Vlado Perkovic, et al.
Pageof 43